HK1154504A1 - Chemokine receptor antagonists and methods of use thereof - Google Patents

Chemokine receptor antagonists and methods of use thereof

Info

Publication number
HK1154504A1
HK1154504A1 HK11108768.0A HK11108768A HK1154504A1 HK 1154504 A1 HK1154504 A1 HK 1154504A1 HK 11108768 A HK11108768 A HK 11108768A HK 1154504 A1 HK1154504 A1 HK 1154504A1
Authority
HK
Hong Kong
Prior art keywords
methods
receptor antagonists
chemokine receptor
chemokine
antagonists
Prior art date
Application number
HK11108768.0A
Other languages
English (en)
Inventor
Jay R Luly
Yoshisuke Nakasato
Etsuo Oshima
Geraldine C B Harriman
Kenneth G Carson
Shomir Ghosh
Amy M Elder
Karen M Mattia
Original Assignee
Millennium Pharm Inc
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/989,086 external-priority patent/US20020169155A1/en
Application filed by Millennium Pharm Inc, Kyowa Hakko Kirin Co Ltd filed Critical Millennium Pharm Inc
Publication of HK1154504A1 publication Critical patent/HK1154504A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
HK11108768.0A 2001-11-21 2011-08-19 Chemokine receptor antagonists and methods of use thereof HK1154504A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/989,086 US20020169155A1 (en) 1998-09-04 2001-11-21 Chemokine receptor anagonists and methods of use therefor

Publications (1)

Publication Number Publication Date
HK1154504A1 true HK1154504A1 (en) 2012-04-27

Family

ID=32713949

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04106595A HK1063789A1 (en) 2001-11-21 2004-09-02 Chemokine receptor antagonists and methods of use thereof
HK11108768.0A HK1154504A1 (en) 2001-11-21 2011-08-19 Chemokine receptor antagonists and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK04106595A HK1063789A1 (en) 2001-11-21 2004-09-02 Chemokine receptor antagonists and methods of use thereof

Country Status (24)

Country Link
EP (3) EP1448566B3 (xx)
JP (5) JP4889920B2 (xx)
KR (3) KR100952767B1 (xx)
CN (3) CN1911930A (xx)
AR (2) AR037394A1 (xx)
AT (1) ATE320431T1 (xx)
AU (1) AU2002352772B2 (xx)
BR (1) BR0213633A (xx)
CA (1) CA2467672C (xx)
CY (1) CY1107243T1 (xx)
DE (2) DE60209937T4 (xx)
DK (1) DK1448566T5 (xx)
ES (2) ES2260497T7 (xx)
HK (2) HK1063789A1 (xx)
IL (3) IL161669A0 (xx)
MY (2) MY142646A (xx)
NO (1) NO328166B1 (xx)
NZ (3) NZ596484A (xx)
PL (2) PL217918B1 (xx)
PT (1) PT1448566E (xx)
SG (2) SG195393A1 (xx)
SI (1) SI1448566T1 (xx)
TW (1) TWI308568B (xx)
ZA (1) ZA200403530B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
NZ596484A (en) * 2001-11-21 2013-05-31 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
WO2009071509A1 (en) * 2007-12-03 2009-06-11 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
TWI431010B (zh) * 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
CN104292142B (zh) * 2013-07-17 2019-05-14 天津大地康和医药技术有限公司 一种n-芳基杂环丁烷脱芳基方法
CN105237455A (zh) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 一种3-取代氮杂环丁烷的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD80449A (xx) *
JPS5250634B2 (xx) 1971-08-23 1977-12-26
JPS61152673A (ja) 1984-12-26 1986-07-11 Kyowa Hakko Kogyo Co Ltd ジベンズ〔ｂ，ｅ〕オキセピン誘導体の製造法
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
NZ228888A (en) 1988-04-28 1991-12-23 Schering Corp Derivatives of piperidine, piperidylidene and piperazine and pharmaceutical compositions
EP0515158A1 (en) 1991-05-23 1992-11-25 Schering Corporation Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
WO1993002081A1 (en) 1991-07-23 1993-02-04 Schering Corporation Novel benzopyrido piperylidene compounds, compositions, methods of manufacture and methods of use
CA2146328C (en) 1992-11-10 2011-08-09 Richard Horuk C-c ckr-1, c-c chemokine receptor
WO1996031469A1 (en) * 1995-04-07 1996-10-10 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
IL124557A0 (en) * 1995-12-15 1998-12-06 Novo Nordisk As Compositions for reducing blood glucose and/or inhibiting the activity of cgrp
US6509346B2 (en) * 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
DE69928226T8 (de) * 1998-01-21 2006-10-19 Millennium Pharmaceuticals, Inc., Cambridge Chemokin rezeptor antagonisten und verwendung
JP2002524461A (ja) * 1998-09-04 2002-08-06 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ケモカイン受容体アンタゴニストおよびその使用方法
AU6503900A (en) * 1999-07-28 2001-02-19 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
AU7912000A (en) 1999-10-20 2001-04-30 Kingspan Industrial Insulation Limited Cellular plastic material based on phenolic resin
TW503427B (en) 2000-07-25 2002-09-21 Koninkl Philips Electronics Nv Display tube comprising a mask with vibration damping means
NZ596484A (en) * 2001-11-21 2013-05-31 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
DE102011084910A1 (de) 2011-10-20 2013-04-25 Wobben Properties Gmbh Verfahren und Vorrichtung zum Einspeisen elektrischen Stroms in ein elektrisches Netz

Also Published As

Publication number Publication date
AU2002352772A1 (en) 2003-06-10
EP2286811B1 (en) 2012-09-05
IL161669A (en) 2010-12-30
TW200303197A (en) 2003-09-01
EP1688418A3 (en) 2008-05-14
MY146601A (en) 2012-08-30
DE60209937T2 (de) 2006-11-30
ES2396186T3 (es) 2013-02-19
NO328166B1 (no) 2009-12-21
NZ596484A (en) 2013-05-31
CN1911930A (zh) 2007-02-14
JP4889920B2 (ja) 2012-03-07
SI1448566T1 (sl) 2006-08-31
SG165152A1 (en) 2010-10-28
CN1585772B (zh) 2014-06-04
KR100919346B1 (ko) 2009-09-25
SG195393A1 (en) 2013-12-30
JP2013209393A (ja) 2013-10-10
NO20042500L (no) 2004-06-15
AR090829A2 (es) 2014-12-10
JP2016138122A (ja) 2016-08-04
PL403800A1 (pl) 2013-08-19
HK1063789A1 (en) 2005-01-14
IL181191A (en) 2012-10-31
EP1448566A2 (en) 2004-08-25
IL181191A0 (en) 2007-07-04
NZ585746A (en) 2011-12-22
JP5878494B2 (ja) 2016-03-08
KR20070118146A (ko) 2007-12-13
MY142646A (en) 2010-12-15
EP1688418B1 (en) 2017-03-15
IL161669A0 (en) 2004-09-27
JP5936669B2 (ja) 2016-06-22
KR20100010952A (ko) 2010-02-02
PL369599A1 (en) 2005-05-02
JP2005510565A (ja) 2005-04-21
CN104031054A (zh) 2014-09-10
CA2467672A1 (en) 2003-06-05
ZA200403530B (en) 2005-07-28
ATE320431T1 (de) 2006-04-15
TWI308568B (en) 2009-04-11
EP1688418A2 (en) 2006-08-09
KR20040064283A (ko) 2004-07-16
EP2286811A1 (en) 2011-02-23
DK1448566T5 (da) 2009-08-03
DE60209937T4 (de) 2009-10-29
ES2260497T3 (es) 2006-11-01
BR0213633A (pt) 2004-08-24
KR100952767B1 (ko) 2010-04-14
EP1448566B3 (en) 2009-04-08
PT1448566E (pt) 2006-08-31
CN1585772A (zh) 2005-02-23
CY1107243T1 (el) 2012-11-21
PL217918B1 (pl) 2014-09-30
DE60209937D1 (de) 2006-05-11
CA2467672C (en) 2011-06-28
DK1448566T3 (da) 2006-07-31
AU2002352772B2 (en) 2006-10-26
EP1448566B1 (en) 2006-03-15
JP2010229136A (ja) 2010-10-14
NZ532827A (en) 2007-09-28
JP2015083577A (ja) 2015-04-30
KR101001092B1 (ko) 2010-12-14
AR037394A1 (es) 2004-11-10
ES2260497T7 (es) 2009-11-05

Similar Documents

Publication Publication Date Title
HK1060727A1 (en) Antagonists of mcp-1 function and methods of use thereof
HK1060728A1 (en) Antagonists of mcp-1 function and methods of use thereof
PL363011A1 (en) Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
EP1541585A4 (en) CXCR4 ANTAGONIST AND USE THEREOF
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
EP1608318A4 (en) CXCR4 ANTAGONISTS AND METHODS OF USE
IL161329A0 (en) Benzamide and heteroarylamide as p2x7 receptor antagonists
AU2002360400A8 (en) Construction and use of micro-electrode arrays
HK1154504A1 (en) Chemokine receptor antagonists and methods of use thereof
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
IL158701A0 (en) Novel use of nk3 receptor antagonist
IL152701A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
EP1536813A4 (en) COMPOSITIONS AND METHODS FOR PROTEIN-ACTIVATED RECEPTOR ANTAGONISTS
AU2003277215A8 (en) Novel neurokinin antagonists and methods of use thereof
IL198759A (en) Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety
AU2003260072A8 (en) Antagonists of chemokine receptors
AU2002351175A8 (en) Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
HUP0401535A3 (en) Somatostatin antagonists and their use
AU3958902A (en) Crf receptor antagonists and methods relating thereto
AU6503900A (en) Chemokine receptor antagonists and methods of use therefor
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
AU6389900A (en) Chemokine receptor antagonists and methods of use therefor
AU2003247052A1 (en) Mcp-1 receptor antagonists and method of use thereof
PL370367A1 (en) Ccr-3 receptor antagonists v
AU2003300396A8 (en) Chemokine antagonists and uses thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161113